Skip to main content

Table 5 Features for prostate cancer selected by MG and known to be involved in this type of cancer

From: A kernel-based integration of genome-wide data for clinical decision support

Outcome* Gene/CNV Hits Region Function Up/down Reference
G SFRP4 55 7p14.1 Inhibitor of PT growth/invasion Up [55]
G VCAN 55 5q14.3 Contributor to PC pathology Up [82]
G ALOX15B 36 17p13.1 Suppressor of PT development Down [54]
S MAGEA4 50 Xq28 Only expressed in PC (diagnosis and therapy) Down [83]
S ANPEP 50 15q25-q26 PT cell invasion Down [84]
S POU4F1 50 13q31.1 PC cell growth Down [85]
S CXCL14 48 5q31 Inhibitor of PT growth Up [56]
S RNASEL 48 1q25 Polymorphic changes as tumor; suppressor in hereditary PC Up [62]
S GDEP 41 4q21.1 Prostate-specific gene Down [86]
M ERG 50 21q22.3 Proto-oncogene; early prostate carcinogenesis Up [57]
M AREG 49 4q13-q21 PC progression/growth via TARP Down [87]
M VAV3 49 1p13.3 Oncogene; PC development/progression Up [59]
M ADAMTS1 26 21q21.2 Negatively affected by TGFbeta1, which increases VCAN-expression Down [82]
R AZGP1 29 7q22.1 Inversely associated to tumor stage; predictor of biochemical recurrence Down [88]
R TIAM1 29 21q22.1-11 Predictor of decreased disease-free survival/recurrence Up [60]
R FGG 28 4q28 PC cell growth Down [89]
R ATF3 26 1q32.3 Inversely related to invasion/angiogenesis; positively correlated to metastases Down [90]
R JAG1 26 20p12.1-11.23 Cell growth/progression/metastasis Up [61]
R ERG 14 21q22.3 Proto-oncogene; early prostate carcinogenesis Up [57]
R ALOX15B 14 17p13.1 Suppressor of PT development Down [54]
  1. *G, GRADE; S, STAGE; M, METASTASIS; R, RECURRENCE. Number of occurrences of the gene/CNV in all LOO iterations (number of LOO iterations for G = 55, S = 50, M = 50, R = 29). Up/down-regulation in high-grade with respect to low-grade; advanced stage with respect to early stage; metastasis with respect to no metastasis; recurrence with respect to no recurrence. PC, prostate cancer; PT, prostate tumor.